Development of New Immunotherapies for Japanese Cedar Pollinosis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Development of New Immunotherapies for Japanese Cedar Pollinosis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 4(2): 193-198.

Author(s): Masahiro Sakaguchi and Kazuki Hirahara.

Affiliation: Laboratory for Allergy Regulation, Research Center for Allergy and Immunology, RIKEN (The Institute of Physical and Chemical Research), 1-7-22 Suehiro-cho, Tsurumiku, Yokohama, Kanagawa, 230-0045 Japan.


We developed new immunotherapies (peptide and DNA vaccines) for treatment of Japanese cedar pollinosis. In the first place, oral administration of a dominant T cell epitope of a major Japanese cedar allergen (Cry j 2) in mice induced immunologic tolerance in both T-helper (Th) 1 and Th2 cell responses against the whole protein allergen. We found that peptide-based oral immunotherapy has a potential efficacy for treatment of the allergic immune response. Further, we developed a hybrid peptide comprising 7 T cell epitopes for human patients. It is expected that the hybrid peptide will downregulate allergen-specific T cells. We are planning a clinical study with the hybrid peptide in the near future. In the second place, we evaluated the use of DNA immunization by inoculating mice with plasmid DNA encoding a major Japanese cedar allergen (Cry j 1) gene. This DNA vaccination suppressed the IgE and IgG1 responses to subsequent alum-precipitated Cry j 1 injections. These results suggest that the DNA vaccination effectively induced Cry j 1-specific Th1-type immune responses, resulting in inhibition of the IgE responses to Cry j 1. Further, we developed DNA vaccine encoding both T cell epitope in Cry j 2 and invariant chain for the delivery of the epitope peptide into major histocompatibility complex (MHC) class II loading pathway. This DNA vaccination also suppressed the IgE responses to subsequent alum-precipitated Cry j 2 injections. DNA vaccine encoding T cell epitope and invariant chain induced epitope-specific T cell responses without allergic side effects.


immunotherapy, allergies, allergen-specific therapy, cryptomeria japonica, peptide vaccine, allergen gene, epitopes.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 2
First Page: 193
Last Page: 198
Page Count: 6
DOI: 10.2174/1568014053507041
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science